论文部分内容阅读
7例临床缓解的急性粒细胞性白血病(AML)病人,每周经皮内或皮下注射BCG和10~9个冷冻保存经过照射的异体AML细胞(由4名AML患者轮流供给)维持缓解,通过补体依赖性和细胞依赖性细胞毒试验,检测患者血清中有无溶自体白血病细胞的抗体。取患者治疗前或复发后的白血病细胞,保存于-179℃,在试验前进行3～7天的短期增殖培养后,用~(51)铬标记,做为靶细胞,在受试病人缓解期间,每月在注入异体AML和BCG之前取血制备血清,并将其保存在-20℃,做为试验血清(抗血清),以混合兔血清为补体,正常人血清为对照
Seven patients with clinical remission of acute myeloid leukemia (AML) were treated with intradermal or subcutaneous injections of BCG and 10 to 9 cryopreserved irradiated allogeneic AML cells (in turn by 4 AML patients). Complement-dependent and cell-dependent cytotoxicity assays detect the presence or absence of antibodies that leach autologous leukemic cells in the patient’s serum. Take leukemia cells before treatment or after relapse, store at -179°C, conduct short-term proliferation cultures for 3 to 7 days before the test, and label with ~(51) chromium as target cells during remission of the patient. , Prepare serum every month before injection of allogeneic AML and BCG, and store it at -20°C as test serum (antiserum), and mix rabbit serum as complement, normal human serum as control.